Advinus Therapeutics Pvt. Ltd.

Bangalore, India

Advinus Therapeutics Pvt. Ltd.

Bangalore, India
Time filter
Source Type

Eurofins Scientific (Paris:ERF) (EUFI.PA), a global leader in bio-pharmaceutical product testing services, announces that it has signed an exclusive agreement with Tata Group to acquire Advinus Therapeutics (“Advinus”), a leading preclinical and clinical phase contract research company for Safety Assessment, DMPK, CMC services, and Analytical R&D Services. The transaction is expected to close in the next few weeks, subject to the fulfilment of customary closing conditions. With over 25 years of GLP compliance and certification, Advinus serves diverse industries such as Biotech, Pharmaceuticals, Biologics, Agrochemicals, Nutraceuticals and Cosmetics. Advinus has submitted over 50 end-to-end investigational new drug applications (INDs) to global regulators such as the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Medicines and Healthcare products Regulatory Agency in the UK (MHRA) and Health Canada among others. Located in Bangalore, India, the company operates a state-of-the art 20,000 m2 facility on a large campus with ample space for expansion. The company generated revenues of EUR 17m in the Fiscal Year ending 31 March 2017 with over 300 staff. Advinus’ expertise complements Eurofins recent contract research, development and manufacturing (CDMO) capabilities following the acquisitions of Alphora in Canada and Amatsigroup in Europe. The company provides GMP testing and manufacturing capabilities, and is well positioned to capitalize on the growing R&D outsourcing market in the Asia-Pacific region. Comment from Mr. KRS Jamwal, Chairman of Advinus and Executive Director of Tata Industries: “Advinus has developed significant promise under Tata parenting, and will now realise its full potential joining the Eurofins family of laboratories. We are confident that with access to Eurofins’ global network and technical competencies, Advinus will be able to rapidly expand its analytical portfolio and services to benefit all its existing and future clients.” Comment from Dr. Gilles Martin, Eurofins CEO: “We are pleased to welcome Advinus Therapeutics to the Eurofins Group. Advinus’ competencies and footprint further strengthen Eurofins’ global leadership in the rapidly-growing biopharmaceutical testing market. We are committed to supporting Advinus’ further development by providing access to the full range of services and capabilities of the Group to the company and its clients.” For more information, please visit Eurofins Scientific through its subsidiaries (hereinafter sometimes “Eurofins” or “the Group”) believes it is the world leader in food, environment and pharmaceutical products testing and that it is also one of the global independent market leaders in certain testing and laboratory services for agroscience, genomics, discovery pharmacology and for supporting clinical studies. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA. With over 30,000 staff in 375 laboratories across 41 countries, Eurofins offers a portfolio of over 130,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group objective is to provide its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff. Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods. As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world. The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP). This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific’ management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantee can be made as to their validity.

— The Pharmaceutical and Healthcare latest pipeline guide Obesity Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Obesity (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Browse Obesity Therapeutic Pipeline report has 96 Company Profiles, 154 Tables and 11 Figures, Spread across 495 Pages Report Available at . Main companies of Obesity Therapeutic Pipeline - Abeome Corp, Adamas Pharmaceuticals Inc, Advinus Therapeutics Ltd, Aegis Therapeutics LLC, Akron Molecules AG, Alize Pharma SAS, Amabiotics SAS, Amgen Inc, Aoxing Pharmaceutical Company Inc, Arrowhead Pharmaceuticals Inc, AstraZeneca Plc, Asubio Pharma Co Ltd, Athersys Inc, Biophytis SAS, BioRestorative Therapies Inc, Biozeus, Boehringer Ingelheim GmbH, Braasch Biotech LLC, C3J Therapeutics Inc, Camurus AB, Carmot Therapeutics Inc, CohBar Inc, CoMentis Inc, Connexios Life Sciences Pvt Ltd, ConSynance Therapeutics Inc, Corium International Inc, Daiichi Sankyo Company Ltd, DiscoveryBiomed Inc, Eisai Co Ltd, Eli Lilly and Company, Esperion Therapeutics Inc, Eternygen GmbH, Evotec AG, F. Hoffmann-La Roche Ltd, FibroGen Inc, Genmedica Therapeutics SL, Gila Therapeutics Inc, Gilead Sciences Inc, GlaxoSmithKline Plc, Glucox Biotech AB, GTx Inc, HanAll Biopharma Co Ltd, Hanmi Pharmaceuticals Co Ltd, Hyundai Pharmaceutical Co Ltd, Immungenetics AG, Intarcia Therapeutics Inc, Ionis Pharmaceuticals Inc, Ixchel Pharma LLC, Jenrin Discovery Inc, Johnson & Johnson, Laboratorios Silanes SA de CV, Lead Discovery Center GmbH, Leading BioSciences Inc, Lotus Pharmaceutical Co Ltd, M Pharmaceutical Inc, Magnus Life Ltd, MedImmune LLC, Merck & Co Inc, Mitochon Pharmaceuticals Inc, Mitsubishi Tanabe Pharma Corp, NeuroNano Pharma Inc, NGM Biopharmaceuticals Inc, NIBEC, Nordic Bioscience A/S, Novartis AG, Discount Available at (This report is available at upto 25% Discount till June 02nd 2017.) The Obesity (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Obesity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Obesity (Metabolic Disorders). The pipeline guide reviews pipeline therapeutics for Obesity (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. The pipeline guide reviews key companies involved in Obesity (Metabolic Disorders) therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Obesity (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Obesity (Metabolic Disorders) Order a copy of this research report at Table of Contents: Introduction Obesity - Overview Obesity - Therapeutics Development Obesity - Therapeutics Assessment Obesity - Companies Involved in Therapeutics Development Obesity - Drug Profiles Obesity - Dormant Projects Obesity - Discontinued Products Obesity - Product Development Milestones Appendix List of Tables. List of Figures. About Us: is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. Call +1 888 391 5441 with your research requirements or email the details at For more information, please visit

Sulaiman S.M.,Dr. M.G.R. Educational and Research Institute | Rajashekhar G.,Dr. M.G.R. Educational and Research Institute | Prakash P.J.,Dr. M.G.R. Educational and Research Institute | Singh D.S.,Advinus Therapeutics Pvt. Ltd. | Saleem C.,Advinus Therapeutics Pvt. Ltd.
Journal of Pharmacology and Toxicology | Year: 2010

The objective of this study was to evaluate the immunoprophylactic activity of immunol, a polyherbal formulation against dexamethasone induced immunosuppression in rats. The rats were administered oral doses of 1, 5 and 10 mL kg-1 b.wt., orally for 28 days following which immunosuppression was induced using dexamethasone (5 mg kg-1, twice daily for 3 days, intraperitoneally). Immunol at the dose of 10 mL kg-1 b.wt. exhibited prophylactic effect against dexamethasone induced immune suppression by way of both cell mediated and humoral mediated immunity. © 2010 Academic Journals Inc.

Thamizhselvi R.K.,Advinus Therapeutics Pvt. Ltd
Indian Journal of Animal Sciences | Year: 2010

A study of 49 contract broiler farmers under 4 leading integrators in and around Puducherry revealed that the contract is one sided favouring the integrator as the contract stipulates standards for the outputs from the farmer but it does not specify any standards for the inputs the integrator supplies such as weight of the day-old chick, quality standards for feed and medicines. The findings also indicated that the weight of the day-old chicks supplied was less than the standard weight of 40 g, an important cause for low body weight gain as well as high mortality. Although the integrators are bearing the risk of production and marketing, the contract broiler farming is exploitative as the integrators are paying on an average 4.61/bird, mostly on the basis of production cost. The integrators may do well by bearing the cost of the miscellaneous inputs being provided by the farmers and by taking feed conversion ratio as the basis for payment rather than production cost on which the farmer has very little control.

Gopinath V.S.,Advinus Therapeutics Pvt. Ltd. | Pinjari J.,Advinus Therapeutics Pvt. Ltd. | Dere R.T.,Advinus Therapeutics Pvt. Ltd. | Verma A.,CSIR - Central Electrochemical Research Institute | And 11 more authors.
European Journal of Medicinal Chemistry | Year: 2013

An analogous library of 2-substituted quinoline compounds was synthesized with the aim to identify a potential drug candidate to treat visceral leishmaniasis. These molecules were tested for their in vitro and in vivo biological activity against Leishmania donovani. Metabolic stability of these compounds was also improved through the introduction of halogen substituents. Compound (26g), found to be the most active; exhibited an IC50 value of 0.2 μM and >180 fold selectivity. The hydrochloride salt of (26g) showed 84.26 ± 4.44 percent inhibition at 50 mg/kg × 5 days (twice daily, oral route) dose in L. donovani/hamster model. The efficacy was well correlated with the PK data observed which indicating that the compound is well distributed. © 2013 Elsevier Masson SAS. All rights reserved.

Sridhara A.M.,Advinus Therapeutics Pvt. Ltd. | Sridhara A.M.,Kuvempu University | Venugopala Reddy K.R.,Kuvempu University | Keshavayya J.,Kuvempu University | And 5 more authors.
European Journal of Medicinal Chemistry | Year: 2010

A series of new 2-substituted [4-(1,3,4-oxadiazol-2-yl)methyl]phthalazin- 1(2H)-one derivatives 7a-h to 9a-h were designed and synthesized from methyl (4-oxo-3,4-dihydrophthalazin-1-yl)acetate (4), which in was turn prepared from phthalic anhydride. The structure of synthesized new compounds were characterized by spectral data and screened for their antimicrobial activities against various bacteria and fungi strains. Several of these compounds showed antimicrobial activity. © 2010 Elsevier Masson SAS. All rights reserved.

Basavaiah K.,University of Mysore | Tharpa K.,University of Mysore | Vinay K.B.,Advinus Therapeutics Pvt. Ltd.
Ecletica Quimica | Year: 2010

Four simple titrimetric procedures are described for the determination of lisinopril (LNP) in bulk and in pharmaceuticals based on the neutralization of basic-amino and acidic carboxylic acid groups present in LNP. Method A is based on the neutralization of basic amino groups using perchloric acid as titrant in anhydrous acetic acid medium. Method B, method C and method D are based on neutralization of carboxylic acid group using NaOH, sodium methoxide and methanolic KOH, as titrants, respectively. Method A is applicable over 2.0-20.0 mg range and the calculations are based in the molar ratio of 1:2 (LNP:HClO4). Method B, method C and method D are applicable over 2.0-20.0 mg, 1.0-10.0 mg and 5.0-15.0 mg range, respectively, and their respective molar ratios are 1:1 (LNP:NaOH), 1:2 (LNP:CH3ONa) and 1:1 (LNP:KOH). Intraday and inter day accuracy and precision of the methods were evaluated and the results showed intra- and inter-day precision less than 2.7% (RSD), and accuracy of < 2.5 % (RE). The developed methods were applied to determine LNP in tablets and the results were validated statistically by comparing the results with those of the reference method by applying the Student's t-test and F-test. The accuracy was further ascertained by recovery studies via standard addition technique. No interferences from common tablet exipients was observed.

Singh U.P.,Indian Institute of Science | Singh U.P.,Advinus Therapeutics Pvt. Ltd.
Journal of Molecular Structure | Year: 2010

Structure of a cyclic water tetramer in channels (pores) formed by self-assembly of N6-methyl-5′-AMP·Na2 molecules is described and a hypothetical model is proposed for growth of water clusters. © 2010 Elsevier B.V. All rights reserved.

Tiwari A.,Advinus Therapeutics Pvt. Ltd.
Drugs of the Future | Year: 2012

Luseogliflozin (TS-071), developed by Taisho Pharmaceutical, is a novel, potent sodium/glucose cotransporter 2 (SGLT2) inhibitor for the potential treatment of type 2 diabetes (T2D) and type 1 diabetes (T1D). Luseogliflozin exhibits high selectivity for SGLT2 over SGLT1 and the glucose transporters GLUT2 and GLUT4, with favorable pharmacokinetic and pharmacodynamic properties. Luseogliflozin exhibited increased urinary glucose excretion, with improved glucose tolerance and a significant reduction in fasting plasma glucose and postprandial plasma glucose, with body weight loss after chronic treatment in different animal models of diabetes and without an increase in plasma insulin. Clinical data in Japanese patients demonstrated that luseogliflozin was orally bioavailable, with a prolonged half-life, suitability for once-daily dosing and effective in significantly reducing glycated hemoglobin and fasting plasma glucose, with body weight loss. Luseogliflozin was well tolerated, without the risk of hypoglycemia and clinically meaningful changes in urinary volume, electrolyte excretion and renal function. The results from phase III clinical trials in T2D and T1D patients will be pivotal; however, the available data suggest that luseogliflozin has potential for success in this niche market segment. Copyright © 2012 Prous Science, S.A.U. or its licensors. All rights reserved.

Hajare A.K.,Advinus Therapeutics Pvt. Ltd | Datrange L.S.,Advinus Therapeutics Pvt. Ltd | Vyas S.,Advinus Therapeutics Pvt. Ltd | Bhuniya D.,Advinus Therapeutics Pvt. Ltd | Reddy D.S.,Advinus Therapeutics Pvt. Ltd
Tetrahedron Letters | Year: 2010

An efficient synthesis of an enantiomer of insect's natural pheromone is reported starting from chiral pool d-(-)-pantolactone. Highly stereoselective tandem conjugate addition/cyclization sequence and hydrogenation of exocyclic double bond are the key steps in the present synthesis. © 2010 Elsevier Ltd. All rights reserved.

Loading Advinus Therapeutics Pvt. Ltd. collaborators
Loading Advinus Therapeutics Pvt. Ltd. collaborators